Schott Pharma plans Frankfurt Stock Exchange listing by end of year to boost offering to injectable drug companies

Drug container supplier Schott Pharma revealed Wednesday it is making plans to be publicly listed on the Frankfurt Stock Exchange by the end of the year in a bid to fund the company’s further expansion into the injectable drug market.

The capital raised will increase the Mainz, Germany-headquartered company’s production capacity at its German and US facilities and fund a new manufacturing site in Hungary. The IPO will also support the company’s goal to become climate-neutral by 2030.

Almuth Steinkühler

Although the company has not disclosed how much it plans to raise, the initial public offering will be made of shares from existing shareholders who will maintain a majority stake in the company. “We have self financed our growth… therefore there’s no need from our perspective to raise any primary proceeds,” CFO Almuth Steinkühler added during a media call.

Schott provides prefillable syringes, cartridges and vials, as well as analytical, development, fill-and-finish and regulatory services for pharma companies and CDMOs. They provide services to companies with injectable approaches, such as mRNA-based products and GLP-1 drugs.

According to the company, the injectable drug market is estimated to grow 9% annually until 2026. Its products made up 47% of its revenue within the first nine months of the 2023 fiscal year.

manufacturing
pharma
shares
fund